Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HMPL-523 in Relapsed/Refractory Hematologic Malignancies
NCT02503033Phase 1Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Nov 2015
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sovleplenib in hematologic malignancy, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 6 more (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoint: Dose Limited Toxicities at 28 days. Status: unknown.
02
Drugs
sovleplenib
03
Conditions
hematologic malignancychronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02503033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503033.